Longeveron Inc. Files 8-K for Other Events
Ticker: LGVN · Form: 8-K · Filed: Jul 17, 2024 · CIK: 1721484
| Field | Detail |
|---|---|
| Company | Longeveron INC. (LGVN) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Longeveron filed an 8-K, likely with important updates. Stay tuned.
AI Summary
Longeveron Inc. filed an 8-K on July 17, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text, but it serves as a notification of these items.
Why It Matters
This filing indicates that Longeveron Inc. is providing updates or disclosures required by the SEC, which could include significant corporate events or financial information relevant to investors.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the lack of specific details in the provided text means the underlying events could be significant, warranting a medium risk assessment until more information is available.
Key Players & Entities
- Longeveron Inc. (company) — Registrant
- July 17, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-40060 (identifier) — Commission File Number
- 47-2174146 (identifier) — IRS Employer Identification No.
- Miami (location) — Principal Executive Offices City
- Florida (location) — Principal Executive Offices State
- 33136 (postal_code) — Principal Executive Offices ZIP
- (305) 909-0840 (phone_number) — Registrant's Telephone Number
FAQ
What specific 'Other Events' are being reported by Longeveron Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' being reported, only that this item is being addressed.
What is the significance of filing 'Financial Statements and Exhibits' as part of this 8-K?
Filing 'Financial Statements and Exhibits' indicates that Longeveron Inc. is providing updated financial information or related documentation as required by the SEC.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K was on July 17, 2024.
What is Longeveron Inc.'s principal executive office address?
Longeveron Inc.'s principal executive office is located at 1951 NW 7th Avenue, Suite 520, Miami, Florida 33136.
What is Longeveron Inc.'s telephone number?
Longeveron Inc.'s telephone number is (305) 909-0840.
Filing Stats: 643 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-07-17 08:30:32
Key Financial Figures
- $0.001 — hich registered Class A Common Stock, $0.001 par value per share LGVN The Nasdaq
Filing Documents
- ea0209541-8k_longeveron.htm (8-K) — 26KB
- ea020954101ex99-1_longeveron.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-061942.txt ( ) — 228KB
- lgvn-20240717.xsd (EX-101.SCH) — 3KB
- lgvn-20240717_lab.xml (EX-101.LAB) — 33KB
- lgvn-20240717_pre.xml (EX-101.PRE) — 22KB
- ea0209541-8k_longeveron_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events On July 17, 2024, Longeveron Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation for the Company's lead investigational product Lomecel-B TM , an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors, for the treatment of mild Alzheimer's disease. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. Fast Track designation is available to a product if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease or condition (or serious aspect of a condition), and it demonstrates the potential to address unmet medical needs for such a disease or condition (i.e., there is no available therapy for the condition, or the condition's treatment or diagnosis is not adequately addressed by currently available therapies). This designation is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product may reach the market expeditiously. Investigational therapies that receive Fast Track designation may be eligible for Priority Review (i.e., review of an application within six (6) months of receipt versus 10 months) if relevant criteria are met at the time of application submission to the FDA, as well as rolling FDA review (i.e., the FDA may consider reviewing portions of an application before the complete application is submitted).
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K. Exhibit No. Description 99.1 Press Release issued by the Company on July 17, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LONGEVERON INC. Date: July 17, 2024 /s/ Wa'el Hashad Name: Wa'el Hashad Title: Chief Executive Officer 2